Abstract
Bromodomains (BRDs) are important protein domains in the reading process of epigenetic marks. Recent studies have demonstrated that human BET protein BRD4 which contains bromodomains plays a critical role in cell proliferation, cancer growth and virus-host pathogenesis. In this work, a chemical-core substitution strategy was employed to identify BRD4 bromodomain inhibitors that had new and different chemical cores featuring common chemical portions with the parent fragments. After the combination of compounds BI2536 and GSK726, two hit compounds 6h and 6i represented potent lead compounds to deserve further optimization. Then, ten analogous compounds were synthesized and evaluated by in-vitro biological test. Among them, compound 6d exhibited the greatest inhibition against BRD4 bromodomains with IC50 value of 180 nM.
Keywords: Epigenetic, BRD4, chemical-core substitution, quinoxalone derivatives, biology, optimization
Letters in Drug Design & Discovery
Title:Synthesis and Biological Activity of Quinoxalone Derivatives as BRD4 Bromodomain Inhibitors
Volume: 14 Issue: 1
Author(s): Bin Xu, Lei-Lei Zhao, Yi-Fei Yang, Jian Zhang, Ling-Yun Yang, Bing Zhang, Li Han, Hui-Bin Zhang and Jin-Pei Zhou
Affiliation:
Keywords: Epigenetic, BRD4, chemical-core substitution, quinoxalone derivatives, biology, optimization
Abstract: Bromodomains (BRDs) are important protein domains in the reading process of epigenetic marks. Recent studies have demonstrated that human BET protein BRD4 which contains bromodomains plays a critical role in cell proliferation, cancer growth and virus-host pathogenesis. In this work, a chemical-core substitution strategy was employed to identify BRD4 bromodomain inhibitors that had new and different chemical cores featuring common chemical portions with the parent fragments. After the combination of compounds BI2536 and GSK726, two hit compounds 6h and 6i represented potent lead compounds to deserve further optimization. Then, ten analogous compounds were synthesized and evaluated by in-vitro biological test. Among them, compound 6d exhibited the greatest inhibition against BRD4 bromodomains with IC50 value of 180 nM.
Export Options
About this article
Cite this article as:
Xu Bin, Zhao Lei-Lei, Yang Yi-Fei, Zhang Jian, Yang Ling-Yun, Zhang Bing, Han Li, Zhang Hui-Bin and Zhou Jin-Pei, Synthesis and Biological Activity of Quinoxalone Derivatives as BRD4 Bromodomain Inhibitors, Letters in Drug Design & Discovery 2017; 14 (1) . https://dx.doi.org/10.2174/1570180813666160715160857
DOI https://dx.doi.org/10.2174/1570180813666160715160857 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Advances in Retroviral Gene Therapy
Current Gene Therapy Extracellular Production of the Oncolytic Enzyme, L-Asparaginase, by Newly Isolated Streptomyces sp. Strain NEAE-95 as Potential Microbial Cell Factories: Optimization of Culture Conditions Using Response Surface Methodology
Current Pharmaceutical Biotechnology Cyclopentenyl Cytosine (CPEC): An Overview of its in vitro and in vivo Activity
Current Cancer Drug Targets Nuclear PI-PLCβ1 and Myelodysplastic Syndromes: Genetics and Epigenetics
Current Pharmaceutical Design BCR/ABL1 Fusion Transcripts Generated from Alternative Splicing: Implications for Future Targeted Therapies in Ph+ Leukaemias
Current Molecular Medicine Dual Inhibition of Cdc7 and Cdk9 by PHA-767491 Suppresses Hepatocarcinoma Synergistically with 5-Fluorouracil
Current Cancer Drug Targets Ferroptosis Inducers for Prostate Cancer Therapy
Current Medicinal Chemistry Diabetes Gene Therapy: Potential and Challenges
Current Gene Therapy Modulation of Antibiotic Efflux in Bacteria
Current Medicinal Chemistry - Anti-Infective Agents Muscarinic Acetylcholine Receptor-Interacting Proteins (mAChRIPs): Targeting the Receptorsome
Current Drug Targets Antimicrobial Activity of New 2-Thioxo-benzo[g]quinazolin-4(3H)-one Derivatives
Medicinal Chemistry Microwave-assisted Cycloaddition Reactions in Carbo- and Heterocyclic Chemistry
Current Organic Chemistry MicroRNA in Multiple Myeloma - A Role in Pathogenesis and Prognostic Significance
Current Medicinal Chemistry CXXC5 Associates with Smads to Mediate TNF-α Induced Apoptosis
Current Molecular Medicine Design, Synthesis and Antiproliferative Activity of 2-Acetamidothiazole-5- carboxamide Derivatives
Medicinal Chemistry Determinants of Left Ventricular Hypertrophy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Low-Dose Methotrexate (LD-MTX) in Rheumatology Practice - A Most Widely Misunderstood Drug
Current Rheumatology Reviews Exposure of B Cell Chronic Lymphocytic Leukemia (B-CLL) Cells to Nutlin-3 Induces a Characteristic Gene Expression Profile, which Correlates with Nutlin-3-Mediated Cytotoxicity (Supplementry Table)
Current Cancer Drug Targets Thymidylate Synthase Gene in Pharmacogenetics
Current Pharmacogenomics Some Implications of Receptor Kinase Signaling Pathway for Development of Multitargeted Kinase Inhibitors
Current Radiopharmaceuticals